



DEPARTMENT OF HEALTH & HUMAN SERVICES

National Institutes of Health
Bethesda, Maryland 20892

April 24, 2012

S. Claiborne Johnston, M.D., Ph.D.
Professor and Associate Vice Chancellor of Research
University of California, San Francisco
505 Parnassus Avenue, Box 0114, M798
San Francisco, CA 94143-0114

Dear Dr. Johnston:

I am writing to confirm that the NINDS-appointed Data and Safety Monitoring Board (DSMB) for your clinical trial, "Platelet-Oriented Inhibition in New TIA and minor ischemic stroke" (POINT), met in Washington, DC on April 2, 2012 to review all interim data from the trial. The DSMB identified no issues of concern regarding safety or study implementation, and thus recommended the study proceed as planned.

The DSMB will meet by teleconference in approximately six months to perform the next interim review.

Sincerely,

A handwritten signature in black ink, appearing to read "Peter R. Gilbert".

Peter R. Gilbert, Sc.M.
Clinical Research Project Manager
Office of Clinical Research
National Institute of Neurological Disorders and Stroke
National Institutes of Health
6001 Executive Boulevard, Suite 2202
Bethesda, MD 20892-9525